Gland Pharma Ltd

GLAND

Company Profile

  • Business description

    Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.

  • Contact

    TSIIC, Phase - IV
    Plot No. 11 and 84
    Pashamylaram (V), Patancheru M
    Sangareddy District
    HyderabadTG502307
    IND

    T: +91 8455699999

    https://www.glandpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2026

    Employees

    4,351

Stocks News & Analysis

stocks

Undervalued by 17%, this US cybersecurity leader is a buy for 2026

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks

Tough conditions for ASX listed wagering leader

Wagering continues to be challenged in Australia.
stocks

Chart of the Week: Inflation fears dampen sentiment on retailers

Rising inflation is the fly in the ointment.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,045.9027.80-0.31%
CAC 408,362.09118.631.44%
DAX 4025,261.64134.180.53%
Dow JONES (US)49,465.15199.040.40%
FTSE 10010,124.6079.910.80%
HKSE26,231.7982.480.32%
NASDAQ23,651.83171.810.73%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,696.2520.61-0.15%
S&P 5006,962.5141.050.59%
S&P/ASX 2008,717.8029.10-0.33%
SSE Composite Index4,120.4337.450.92%

Market Movers